Q2 EPS Estimates for DENTSPLY SIRONA Raised by Analyst

DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report) - Investment analysts at Barrington Research lifted their Q2 2025 earnings per share estimates for DENTSPLY SIRONA in a research note issued on Monday, May 12th. Barrington Research analyst M. Petusky now expects that the medical instruments supplier will earn $0.51 per share for the quarter, up from their prior estimate of $0.50. Barrington Research has a "Outperform" rating and a $21.00 price objective on the stock. The consensus estimate for DENTSPLY SIRONA's current full-year earnings is $1.84 per share. Barrington Research also issued estimates for DENTSPLY SIRONA's Q3 2025 earnings at $0.49 EPS, Q4 2025 earnings at $0.47 EPS, Q1 2026 earnings at $0.46 EPS, Q2 2026 earnings at $0.55 EPS, Q3 2026 earnings at $0.55 EPS, Q4 2026 earnings at $0.54 EPS and FY2027 earnings at $2.28 EPS.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.29 by $0.14. DENTSPLY SIRONA had a positive return on equity of 12.62% and a negative net margin of 10.59%. The firm had revenue of $879.00 million during the quarter, compared to the consensus estimate of $854.75 million. During the same period last year, the company earned $0.42 earnings per share. The company's revenue was down 7.8% on a year-over-year basis.

Several other research firms also recently commented on XRAY. UBS Group reduced their price objective on DENTSPLY SIRONA from $27.00 to $25.00 and set a "buy" rating for the company in a report on Friday, May 9th. Morgan Stanley downgraded DENTSPLY SIRONA from an "overweight" rating to an "equal weight" rating and set a $14.00 price objective for the company. in a report on Tuesday, April 15th. Jefferies Financial Group downgraded DENTSPLY SIRONA from a "buy" rating to a "hold" rating and reduced their price objective for the stock from $30.00 to $20.00 in a report on Thursday, January 23rd. Robert W. Baird reduced their price objective on DENTSPLY SIRONA from $22.00 to $20.00 and set a "neutral" rating for the company in a report on Friday, February 28th. Finally, Wells Fargo & Company reduced their price objective on DENTSPLY SIRONA from $20.00 to $19.00 and set an "equal weight" rating for the company in a report on Friday, February 28th. Eleven equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $20.36.

DENTSPLY SIRONA Stock Up 1.2%

Shares of NASDAQ:XRAY traded up $0.20 on Tuesday, hitting $16.70. 2,469,701 shares of the company traded hands, compared to its average volume of 2,965,827. DENTSPLY SIRONA has a 52 week low of $12.16 and a 52 week high of $28.44. The company has a quick ratio of 0.84, a current ratio of 1.25 and a debt-to-equity ratio of 0.72. The stock has a 50 day simple moving average of $14.41 and a 200-day simple moving average of $17.38. The company has a market cap of $3.33 billion, a PE ratio of -8.07, a PEG ratio of 1.80 and a beta of 0.92.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in shares of DENTSPLY SIRONA by 2.8% during the 1st quarter. Vanguard Group Inc. now owns 20,740,589 shares of the medical instruments supplier's stock valued at $309,864,000 after buying an additional 557,329 shares in the last quarter. First Eagle Investment Management LLC lifted its position in shares of DENTSPLY SIRONA by 2.5% during the 4th quarter. First Eagle Investment Management LLC now owns 14,500,409 shares of the medical instruments supplier's stock valued at $275,218,000 after buying an additional 348,532 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of DENTSPLY SIRONA by 11.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 13,961,759 shares of the medical instruments supplier's stock valued at $208,590,000 after buying an additional 1,412,517 shares in the last quarter. Nuance Investments LLC lifted its position in shares of DENTSPLY SIRONA by 25.0% during the 4th quarter. Nuance Investments LLC now owns 13,545,981 shares of the medical instruments supplier's stock valued at $257,103,000 after buying an additional 2,708,097 shares in the last quarter. Finally, Fuller & Thaler Asset Management Inc. lifted its position in shares of DENTSPLY SIRONA by 4.7% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 12,077,949 shares of the medical instruments supplier's stock valued at $180,445,000 after buying an additional 538,531 shares in the last quarter. 95.70% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Gregory T. Lucier bought 15,142 shares of the company's stock in a transaction on Monday, March 3rd. The shares were acquired at an average cost of $16.51 per share, with a total value of $249,994.42. Following the completion of the transaction, the director now owns 81,971 shares of the company's stock, valued at approximately $1,353,341.21. This trade represents a 22.66% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.50% of the company's stock.

DENTSPLY SIRONA Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, April 11th. Shareholders of record on Friday, March 28th were given a $0.16 dividend. The ex-dividend date of this dividend was Friday, March 28th. This represents a $0.64 annualized dividend and a yield of 3.83%. DENTSPLY SIRONA's payout ratio is -14.10%.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.